What are the recommended doses, administration routes, contraindications, and precautions for using sumatriptan in adults with acute migraine?

Sumatriptan for Acute Migraine in Adults

Sumatriptan should be added to an NSAID (or acetaminophen when NSAIDs are contraindicated) when first-line therapy with NSAIDs or acetaminophen alone fails to provide adequate pain relief for moderate to severe episodic migraine. 1

Recommended Dosing and Administration Routes

Oral Administration

• Standard dosing: 50 mg or 100 mg as a single dose at migraine onset 2, 3
• The 50 mg dose provides similar efficacy to 100 mg with fewer adverse events 3
• The 25 mg dose is less effective than 50 mg or 100 mg 3
• Maximum daily dose: 200 mg in 24 hours 2
• Repeat dosing: A second dose may be considered only if some response occurred to the first dose, separated by at least 2 hours 2
• Hepatic impairment: Maximum single dose should not exceed 50 mg in mild to moderate hepatic impairment 2

Subcutaneous Administration

• Standard dosing: 6 mg as a single dose 4
• Most effective route: Provides pain-free response in approximately 59% of patients at 2 hours (NNT 2.3) compared to 15% with placebo 5, 4
• Fastest onset: Relief begins within 15 minutes for cluster headache and provides more rapid relief than oral routes for migraine 6, 4
• Alternative 4 mg dose available but 6 mg is superior for pain-free response at one hour 4

Intranasal Administration

• Standard dosing: 20 mg provides optimal efficacy (NNT 3.5 for headache relief at 2 hours) 5
• Lower doses (5 mg, 10 mg) are available but less effective 5

Rectal Administration

• Standard dosing: 25 mg (NNT 2.4 for headache relief at 2 hours) 5
• Limited data available but effective option 5

Route Selection for Specific Situations

• Severe nausea or vomiting: Use nonoral triptan (subcutaneous, intranasal, or rectal) with an antiemetic 1
• Emergency department: Subcutaneous sumatriptan should be offered for parenteral therapy (level B recommendation) 7

Absolute Contraindications

Sumatriptan must not be used in patients with: 2

• History of coronary artery disease or coronary artery vasospasm
• Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders
• History of stroke, transient ischemic attack, hemiplegic or basilar migraine
• Peripheral vascular disease
• Ischemic bowel disease
• Uncontrolled hypertension
• Recent use (within 24 hours) of another 5-HT1 agonist (triptan) or ergotamine-containing medication
• Concurrent or recent (past 2 weeks) use of monoamine oxidase-A inhibitor
• Hypersensitivity to sumatriptan (angioedema and anaphylaxis reported)
• Severe hepatic impairment

Critical Precautions and Warnings

Cardiovascular Risks

• Myocardial ischemia/infarction and Prinzmetal's angina: Perform cardiac evaluation in patients with multiple cardiovascular risk factors before initiating therapy 2
• Arrhythmias: Discontinue if they occur 2
• Chest/throat/neck/jaw symptoms: While generally not associated with myocardial ischemia, evaluate for coronary artery disease in high-risk patients 2
• Real-world data shows cardiac arrhythmia is the most common contraindication among patients prescribed triptans (8.4%), followed by cerebrovascular disease (3.7%) and coronary artery disease (2.6%) 8

Cerebrovascular and Vascular Events

• Cerebral hemorrhage, subarachnoid hemorrhage, and stroke: Discontinue immediately if these occur 2
• Gastrointestinal ischemic reactions and peripheral vasospastic reactions: Discontinue if these develop 2

Medication Overuse Headache

• Critical threshold: Limit use to <10 days per month to avoid medication overuse headache 1
• This threshold is lower than NSAIDs (≥15 days per month) 1
• Detoxification may be necessary if overuse occurs 2

Serotonin Syndrome

• Risk with concomitant serotonergic drugs: Discontinue immediately if serotonin syndrome develops 2
• Monitor when combining with SSRIs, SNRIs, or other serotonergic medications

Seizures

• Use with caution in patients with epilepsy or lowered seizure threshold 2

Special Populations

Pregnancy and Lactation

• Not recommended: Contraindicated in pregnant and lactating women per guideline applicability 1
• Counseling required: Discuss adverse effects during pregnancy and lactation with patients of childbearing potential 1
• Animal data suggest potential for fetal harm 2

Hepatic Impairment

• Mild to moderate: Maximum single dose 50 mg 2
• Severe: Contraindicated 2

Optimal Treatment Strategy

Stepwise Approach

1. First-line: NSAID or acetaminophen at adequate doses 1
2. Second-line: Add triptan (including sumatriptan) to NSAID or acetaminophen when first-line therapy fails 1
3. Combination therapy: Counsel patients to use combination therapy (triptan with NSAID or acetaminophen) from onset for improved efficacy 1

Timing of Administration

• Early treatment is superior: Initiate treatment as soon as possible after migraine onset 1
• Taking medication when pain is mild is more effective than waiting until pain is moderate or severe 5
• Do not use during aura: Sumatriptan should not be given during the migraine aura phase 6

Triptan Selection Within Class

• Choice among triptans (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan) should be individualized based on route of administration preference and cost 1
• Patients who do not respond to one triptan may respond to another within the same class 1

Common Adverse Events

Oral Sumatriptan

• Nausea, vomiting, malaise, fatigue, dizziness 6
• Paresthesia, warm/cold sensation 2
• Chest pain/tightness/pressure and/or heaviness 2
• Neck/throat/jaw pain/tightness/pressure 2
• Adverse events with 50 mg similar to placebo and lower than 100 mg 3

Subcutaneous Sumatriptan

• Injection site reactions in approximately 30% 6
• Chest symptoms in 3-5% (rarely associated with myocardial ischemia) 6
• Higher incidence of adverse events compared to oral routes but generally transient and mild 5, 4

Headache Recurrence

• Occurs in 26-48% of patients within 24 hours after initial response 3
• Effectively treated with a second dose 6, 3
• No evidence that a second 6 mg subcutaneous dose after inadequate first response improves outcomes 4

Clinical Pitfalls to Avoid

• Do not use opioids or butalbital for acute episodic migraine treatment 1
• Do not exceed frequency limits: Monitor for medication overuse headache with use ≥10 days per month 1
• Do not combine with vasoconstrictive substances: Never give with ergotamines or methysergide 6
• Do not use without clear migraine diagnosis: Reconsider diagnosis if no response to first treated attack 2
• Not for prevention: Sumatriptan is indicated only for acute treatment, not migraine prevention 2
• Not for cluster headache (oral formulation): While subcutaneous sumatriptan 6 mg is effective for cluster headache, oral formulations lack established efficacy for this indication 2